Enantioselective analysis of citalopram and escitalopram in postmortem blood together with genotyping for CYP2D6 and CYP2C19

Journal of Analytical Toxicology

Volumn 33, Issue 2, 2009, Pages 65-76

  Carlsson, Björn ^a   Holmgren, Anita ^a   Ahlner, Johan ^a   Bengtsson, Finn ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ALIMEMAZINE; CAFFEINE; CARBON MONOXIDE; CARISOPRODOL; CITALOPRAM; CODEINE; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; ESCITALOPRAM; MEPROBAMATE; NORDAZEPAM; NORTRIPTYLINE; OXAZEPAM; PARACETAMOL; TRAMADOL; ZOPICLONE;

ARTICLE; AUTOPSY; DRUG BLOOD LEVEL; ENANTIOSELECTIVITY; GAS CHROMATOGRAPHY; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN;

EID: 62549104696     PISSN: 01464760     EISSN: 01464760     Source Type: Journal    
DOI: 10.1093/jat/33.2.65     Document Type: Article

References (47)

1. G. Isacsson, P. Holmgren, H. Druid, and U. Bergman. Psychotropics and suicide prevention. Implications from toxicological screening of 5281 suicides in Sweden 1992-1994. Br. J. Psychiatry 174: 259-265 (1999).
2. G. Isacsson, P. Holmgren, and J. Ahlner. Selective serotonin reuptake inhibitor antidepressants and the risk of suicide: a controlled forensic database study of 14,857 suicides. Acta Psychiatr. Scand. 111: 286-290 (2005).
3. C. Hiemke and S. Hartter. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol. Ther. 85:11-28 (2000).
4. K. Rickels and E. Schweizer. Clinical overview of serotonin reuptake inhibitors. J. Clin. Psychiatry 51: 9-12 (1990).
5. R.J. Milne and K.L. Goa. Citalopram. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs 41: 450-477 (1991).
6. S. Dhillon, L.J. Scott, and G.L. Plosker. Escitalopram: a review of its use in the management of anxiety disorders. CNS Drugs 20:763-790 (2006).
7. D. Murdoch and S.J. Keam. Escitalopram: A review of its use in the management of major depressive disorder. Drugs 65: 2379-2404 (2005).
8. N. Rao. The clinical pharmacokinetics of escitalopram. Clin. Phar-macokinet. 46: 281-290 (2007).
9. J. Sidhu, M. Priskorn, M. Poulsen, A. Segonzac, G. Grollier, and F. Larsen. Steady-state pharmacokinetics of the enantiomers of citalopram and its metabolites in humans. Chirality 9: 686-692 (1997).
10. L. Bertilsson. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin. Pharmacokinet. 29:192-209 (1995).
11. S.M. de Morais, G.R. Wilkinson, J. Blaisdell, K. Nakamura, U.A. Meyer, and J.A. Goldstein. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J. Biol. Chem. 269: 15419-15422 (1994).
12. S.H. Sindrup, K. Brosen, M.G. Hansen, T. Aaes-Jorgensen, K.F. Overo, and L.F. Gram. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther. Drug Monit. 15:11-17 (1993).
13. O.V. Olesen and K. Linnet. Studies on the stereoselective metabolism of citalopram by human liver microsomes and cDNA-expressed cytochrome P450 enzymes. Pharmacology 59: 298-309 (1999).
14. B. Rochat, M. Amey, M. Gillet, U.A. Meyer, and P. Baumann. Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver micro-somes. Pharmacogenetics 7: 1-10 (1997).
15. K. Herrlin, N. Yasui-Furukori, G. Tybring, J. Widen, L.L. Gustafsson, and L. Bertilsson. Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes. Br. J. Clin. Pharmacol. 56: 415-421 (2003).
16. I. Rudberg, M. Hendset, L.H. Uthus, E. Molden, and H. Refsum. Heterozygous mutation in CYP2C19 significantly increases the concentration/dose ratio of racemic citalopram and escitalopram (S-citalopram). Ther. DrugMonit. 28:102-105 (2006).
17. L.L. von Moltke, D.J. Greenblatt, J.M. Grassi, B.W. Granda, K. Venkatakrishnan, S.X. Duan, S.M. Fogelman, J.S. Harmatz, and R.I. Shader. Citalopram and desmethylcitalopram in vitro: human cytochromes mediating transformation, and cytochrome inhibitory effects. Biol. Psychiatry 46: 839-849 (1999).
18. L. Wojnowski and L.K. Kamdem. Clinical implications of CYP3A polymorphisms. Expert Opin. Drug Metab. Toxicol. 2: 171-182 (2006).
19. R.J. Edwards, R.J. Price, P.S. Watts, A.B. Renwick, J.M. Tredger, A.R. Boobis, and B.G. Lake. Induction of cytochrome P450 enzymes in cultured precision-cut human liver slices. Drug Metab. Dispos. 31: 282-288 (2003).
20. M. Ingelman-Sundberg and W.E. Evans. Unravelling the functional genomics of the human CYP2D6 gene locus. Pharmacogenetics 11: 553-554 (2001).
21. A. Jonsson, P. Holmgren, and J. Ahlner. Fatal intoxications in a Swedish forensic autopsy material during 1992-2002. Forensic Sci. Int. 143: 53-59 (2004).
22. G. Isacsson, P. Holmgren, H. Druid, and U. Bergman. The utilization of antidepressants-a key issue in the prevention of suicide: an analysis of 5281 suicides in Sweden during the period 1992-1994. Acta Psychiatr. Scand. 96: 94-100 (1997).
23. G.K. Isbister, S.J. Bowe, A. Dawson, and I.M. Whyte. Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J. Toxicol. Clin. Toxicol. 42: 277-285 (2004).
24. A. Koski, E. Vuori, and I. Ojanpera. Newer antidepressants: evaluation of fatal toxicity index and interaction with alcohol based on Finnish postmortem data. Int. J. Legal Med. 119: 344-348 (2005).
25. L. Grundemar, B. Wohlfart, C. Lagerstedt, F. Bengtsson, and G. Eklundh. Symptoms and signs of severe citalopram overdose. Lancet 349:1602 (1997).
26. M. Personne, G. Sjoberg, and H. Persson. Citalopram overdose-review of cases treated in Swedish hospitals. J. Toxicol. Clin. Toxicol. 35: 237-240(1997).
27. M. Ostrom, A. Eriksson, J. Thorson, and O. Spigset. Fatal overdose with citalopram. Lancet 348: 339-340 (1996).
28. K. Worm, C. Dragsholt, K. Simonsen, and B. Kringsholm. Citalo-pram concentrations in samples from autopsies and living persons. Int. J. Legal Med. 111:188-190 (1998).
29. H. Druid and P. Holmgren. A compilation of fatal and control concentrations of drugs in postmortem femoral blood. J. Forensic Sci. 42: 79-87 (1997).
30. F. LoVecchio, D. Watts, J. Winchell, J. Knight, and T. McDowell. Outcomes after supratherapeutic escitalopram ingestions. J. Emerg. Med. 30: 17-19 (2006).
31. G. Vari and M. Beckson. Escitalopram-associated serotonin toxicity. J. Clin. Psychopharmacol. 27: 229-230 (2007).
32. B. Carlsson and B. Norlander. Optimization and characterization of the chiral separation of citalopram and its demethylated metabolites by response surface methodology. Chromatographia 53:266-272 (2001).
33. P. Holmgren, B. Carlsson, A.L. Zackrisson, B. Lindblom, M.L. Dahl, M.G. Scordo, H. Druid, and J. Ahlner. Enantioselective analysis of citalopram and its metabolites in postmortem blood and genotyping for CYD2D6 and CYP2C19. J. Anal. Toxicol. 28: 94-104 (2004).
34. B. Rochat, M. Amey, and P. Baumann. Analysis of enantiomers of citalopram and its demethylated metabolites in plasma of depressive patients using chiral reverse-phase liquid chromatography. Ther. Drug Monit. 17: 273-279 (1995).
35. B. Carlsson and B. Norlander. Solid-phase extraction with end-capped C2 columns for the routine measurement of racemic citalo-pram and metabolites in plasma by high-performance liquid chromatography. J. Chromatogr. B Biomed. Sci. Appl. 702:234-239 (1997).
36. S. Gustincich, G. Manfioletti, G. Del Sal, C. Schneider, and P. Carninci. A fast method for high-quality genomic DNA extraction from whole human blood. Biotechniques 11: 298-300, 302 (1991).
37. A.L. Zackrisson and B. Lindblom. Identification of CYP2D6 alleles by single nucleotide polymorphism analysis using pyrosequencing. Eur. J. Clin. Pharmacol. 59: 521-526 (2003).
38. E. Soderback, A.L. Zackrisson, B. Lindblom and A. Alderborn. Determination of CYP2D6 gene copy number by pyrosequencing. Clin. Chem. 51: 522-531 (2005).
39. M. Hersberger, J. Marti-Jaun, K. Rentsch, and E. Hanseler. Rapid detection of the CYP2D6*3, CYP2D6*4, and CYP2D6* 6 alleles by tetra-primer PCR and of the CYP2D6*5 allele by multiplex long PCR. Clin. Chem. 46: 1072-1077 (2000).
40. S. Eriksson, L.M. Berg, M. Wadelius, and A. Alderborn. Cytochrome p450 genotyping by multiplexed real-time dna sequencing with pyrosequencing technology. Assay Drug Dev. Technol. 1:49-59 (2002).
41. A.L. Zackrisson, P. Holmgren, A.B. Gladh, J. Ahlner, and B. Lind-blom. Fatal intoxication cases: cytochrome P450 2D6 and 2C19 genotype distributions. Eur. J. Clin. Pharmacol. 60: 547-552 (2004).
42. B. Carlsson, G. Olsson, M. Reis, J. Walinder, C. Nordin, J. Lund- mark, M.G. Scordo, M.L. Dahl, F. Bengtsson, and J. Ahlner. Enan-tioselective analysis of citalopram and metabolites in adolescents. Ther. Drug Monit. 23: 658-664 (2001).
43. M. Reis, M.D. Cherma, B. Carlsson, and F. Bengtsson. Therapeutic drug monitoring of escitalopram in an outpatient setting. Ther. Drug Monit. 29: 758-766 (2007).
44. K.E. Rodda and O.H. Drummer. The redistribution of selected psychiatric drugs in post-mortem cases. Forensic Sci. Int. 164:235-239 (2006).
45. M. Reis, T. Aamo, J. Ahlner, and H. Druid. Reference concentrations of antidepressants. A compilation of postmortem and therapeutic levels. J. Anal. Toxicol. 31: 254-264 (2007).
46. F.C. Kugelberg, M. Kingback, B. Carlsson, and H. Druid. Early-phase postmortem redistribution of the enantiomers of citalopram and its demethylated metabolites in rats. J. Anal. Toxicol. 29:223-228 (2005).
47. F.C. Kugelberg, H. Druid, B. Carlsson, J. Ahlner, and F. Bengtsson. Postmortem redistribution of the enantiomers of citalopram and its metabolites: an experimental study in rats. J. Anal. Toxicol. 28: 631-637 (2004).